Point72 Asset Management L.P. bought a new position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 166,500 shares of the company’s stock, valued at approximately $5,989,000. Point72 Asset Management L.P. owned approximately 0.44% of Eidos Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the business. Cormorant Asset Management LP grew its holdings in Eidos Therapeutics by 8.7% during the 2nd quarter. Cormorant Asset Management LP now owns 551,921 shares of the company’s stock worth $17,154,000 after acquiring an additional 44,357 shares in the last quarter. Vanguard Group Inc. grew its holdings in Eidos Therapeutics by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 376,178 shares of the company’s stock worth $11,692,000 after acquiring an additional 11,857 shares in the last quarter. State Street Corp grew its holdings in Eidos Therapeutics by 0.7% during the 3rd quarter. State Street Corp now owns 218,320 shares of the company’s stock worth $7,853,000 after acquiring an additional 1,523 shares in the last quarter. Northern Trust Corp grew its holdings in Eidos Therapeutics by 1.5% during the 2nd quarter. Northern Trust Corp now owns 184,115 shares of the company’s stock worth $5,723,000 after acquiring an additional 2,647 shares in the last quarter. Finally, Alps Advisors Inc. bought a new stake in shares of Eidos Therapeutics in the 2nd quarter valued at about $2,395,000. Institutional investors own 30.46% of the company’s stock.
In other Eidos Therapeutics news, insider Jonathan C. Fox sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $56.33, for a total transaction of $563,300.00. Also, CFO Christine Siu sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $57.48, for a total transaction of $2,011,800.00. Insiders have sold a total of 82,500 shares of company stock valued at $4,480,775 over the last three months. 70.10% of the stock is currently owned by insiders.
Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.48. The business had revenue of $26.69 million for the quarter. On average, equities analysts predict that Eidos Therapeutics Inc will post -1.07 EPS for the current year.
A number of research firms have recently weighed in on EIDX. Barclays cut shares of Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $37.00 to $45.00 in a report on Friday, November 1st. Roth Capital raised their price target on shares of Eidos Therapeutics from $51.00 to $57.00 and gave the company a “buy” rating in a report on Friday, November 1st. ValuEngine cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Piper Jaffray Companies raised their price target on shares of Eidos Therapeutics from $55.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 19th. Finally, BTIG Research set a $56.00 price target on shares of Eidos Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $52.00.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Read More: Cost of Debt
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.